Korean Journal of Food Science and Technology (한국식품과학회지)

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of a Mixed Extract of Fenugreek Seeds and Lespedeza cuneata on Testosterone Deficiency Syndrome

호로파와 야관문 복합추출물의 남성갱년기 개선에 관한 연구

  • Received : 2015.01.29
  • Accepted : 2015.06.06
  • Published : 2015.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Testosterone deficiency syndrome (TDS) is normally observed in elderly men and is a clinical and biochemical syndrome, characterized by a decline in plasmic testosterone levels resulting in a significant decrease in quality of life. The aim of this study was to evaluate the effect of a mixed extract of fenugreek seeds and Lespedeza cuneata (YHM) on TDS. Rats were divided into three groups: the negative control, YHM-40 (40 mg/kg), and YHM-80 (80 mg/kg) groups. After 4 weeks of YMH administration, an increase was observed in the plasmic testosterone levels, vastus lateralis muscular strength, forced swimming time, total sperm counts, and motile sperm counts in YHM-40 and YHM-80 groups compared to the negative control group. Moreover, sex hormone binding globulin, the epididymal fat pad, total plasmic cholesterol, and triglyceride levels were significantly decreased in the YHM-fed groups. However, prostate specific antigen, aspartate aminotransferase, and alanine aminotransferase levels did not differ among the groups. These results suggest that YHM may enhance testosterone levels in elderly men and alleviate TDS without common side effects.

본 연구에서는 야관문, 호로파 복합추출인 YHM이 남성갱년기증상의 완화에 영향을 미치는 지를 알아보기 위해 흰쥐에게 YHM을 4주간 투여한 후, testosterone, SHBG, PSA, 체지방, 혈중지방, 근육량, 운동수행능력, 정자수, 간독성 등에 미치는 영향을 조사하였다. YHM 투여 후 남성갱년기의 지표로 사용되는 남성호르몬인 testosterone이 유의적으로 증가하였고, testosterone과 결합하여 기능을 저하시키는 SHBG의 농도는 감소하였다. 또한 남성호르몬 보충요법에서 나타날 수 있는 전립선 관련 부작용을 알아보기 위해 PSA를 측정하였으나, 대조군과 별다른 차이를 나타내지는 않았다. 지방조직과 근육량을 측정한 결과 지방 조직은 줄이고 근육량은 늘리는 것으로 나타나 남성갱년기에서 흔히 있는 근육량 감소 및 체지방 증가를 완화시킬 수 있을 것으로 생각된다. 아울러 혈중지질농도에 있어서도 YHM 투여군이 대조군에 비해 총 콜레스테롤과 중성지방은 감소한 반면 고밀도 콜레스테롤은 증가하였음을 관찰하였다. 강제수영을 통한 운동수행능력 측정에서도 YHM 투여군이 대조군에 비하여 수영시간이 길었고 이는 YHM의 투여가 운동수행능력 향상에 도움을 준 것으로 볼 수 있다. 총 정자수와 활동성 정자수를 측정한 결과에서도 YHM 투여군이 유의적으로 증가한 것으로 나타났고 이는 정자형성과 활동성에 영향을 주는 testosterone 농도의 증가에 기인한 것으로 생각된다. 마지막으로 YHM의 투여가 간독성을 가지는지를 알아보기 위해 AST와 ALT를 측정한 결과 대조군과 별다른 차이를 나타내지 않음으로써 간독성을 가지지는 않는 것으로 판단하였다. 또한, 실험결과 전반적으로 저농도 투여군인 YHM-40에서 고농도 투여군인 YHM-80에서 보다 긍정적인 효과를 나타냈다. 이는 YHM의 효과가 농도 의존적이지 않다는 것을 의미하며, 최적의 생체 이용률을 나타내는 농도가 YHM 40mg/kg인 것으로 판단된다. 결론적으로 YHM의 투여는 남성갱년기에 나타나는 여러 가지 지표들을 개선시키는 것으로 나타났고, 이를 활용하여 남성갱년기 개선에 도움을 줄 수 있는 건강기능성식품 소재로 개발할 수 있을 것으로 기대된다.

Keywords

References

  1. Becker HWG. Testicular dysfunction in systemic diseases. pp. 1150-1156. In: Principles and practice of endocrinology and metabolism, Backer KL (ed). Lippincott Co., Philadelphia, PA, USA (2000)
  2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J. Clin. Endocr. Metab. 92: 4241-4247 (2007) https://doi.org/10.1210/jc.2007-1245
  3. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. J. Sex. Med. 7: 1627-1656 (2010) https://doi.org/10.1111/j.1743-6109.2010.01780.x
  4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J. Clin. Endocr. Metab. 91:1995-2010 (2006) https://doi.org/10.1210/jc.2005-2847
  5. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FCW. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J. Androl. 27: 135-137 (2006) https://doi.org/10.2164/jandrol.05047
  6. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FCW. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 12: 5-12 (2009) https://doi.org/10.1080/13685530802389628
  7. Singh P. Andropause: Current concepts. Indian J. Endocrinol. Metab. 17 (Suppl 3): S621-629 (2013) https://doi.org/10.4103/2230-8210.123552
  8. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J. Clin. Endocr. Metab. 95: 2536-2559 (2010) https://doi.org/10.1210/jc.2009-2354
  9. Werner AA. The male climacteric: Report of two hundred and seventy-three casas. J. Amer. Med. Assoc. 132: 188-194 (1946) https://doi.org/10.1001/jama.1946.02870390004002
  10. Shores MM, Matsumoto AM. Testosterone, aging and survival: biomarker or deficiency. Curr. Opin. Endocrinol. Diabetes Obes. 21: 209-216 (2014) https://doi.org/10.1097/MED.0000000000000057
  11. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts male aging study. J. Clin. Endocr. Metab. 73: 1016-1025 (1991) https://doi.org/10.1210/jcem-73-5-1016
  12. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocr. Metab. 86: 724-731 (2001) https://doi.org/10.1210/jcem.86.2.7219
  13. Wu FCW, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D. Hypothalamicpituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European male aging study. J. Clin. Endocr. Metab. 93: 2737-2745 (2008) https://doi.org/10.1210/jc.2007-1972
  14. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: Potential benefits and risks. J. Am. Geriatr. Soc. 51: 101-115 (2003) https://doi.org/10.1034/j.1601-5215.2002.51018.x
  15. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. New Engl. J. Med. 350: 482-1492 (2004) https://doi.org/10.1056/NEJMra022251
  16. Muller M, van der Schouw YT, Thijssen JHH, Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. J. Clin. Endocr. Metab. 88: 5076-5086 (2003) https://doi.org/10.1210/jc.2003-030611
  17. Duru M, Erdogan Z, Duru A, Kucukgul A, Duzguner V, Kaya DA, Sahin A. Effect of seed powder of a herbal legume fenugreek (Trigonella foenum-graceum L.) on growth performance, body components, digestive parts, and blood parameters of broiler chicks. Pakistan J. Zool. 45: 1007-1014 (2013)
  18. Yadav UC, Baquer NZ. Pharmacological effects of Trigonella foenum-graecum L. in health and disease. Pharm. Biol. 52: 243-254 (2014) https://doi.org/10.3109/13880209.2013.826247
  19. Kassem A, Al-Aghbari A, AL-Habori M, Al-Mamary M. Evaluation of the potential antifertility effect of fenugreek seeds in male and female rabbits. Contraception 73: 301-306 (2006) https://doi.org/10.1016/j.contraception.2005.08.020
  20. Aswar U, Bodhankar SL, Mohan V, Thakurdesai PA. Effect of furostanol glycosides from Trigonella foenum-graecum on the reproductive system of male albino rats. Phytother. Res. 24: 1482-1488 (2010) https://doi.org/10.1002/ptr.3129
  21. Lee JK, Kang DG, Lee HS. Vascular relaxation induced by aqueous extract of Lespedeza cuneata via the NO-cGMP pathway. J. Nat. Med. 66: 17-24 (2012) https://doi.org/10.1007/s11418-011-0546-6
  22. Park SY, Kim HH. Effect of Lespedezea cuneata on the contraction of rabbit common carotid artery and corpus cavernosum. Korean J. Orient. Physiol. Pathol. 27: 809-817 (2013)
  23. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. J. Clin. Endocrinol. 63: 381-394 (2005) https://doi.org/10.1111/j.1365-2265.2005.02350.x
  24. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: The Massachusetts male ageing study. J. Clin. Endocrinol. 65 :125-131 (2006) https://doi.org/10.1111/j.1365-2265.2006.02560.x
  25. Morales A, Schulman CC, Tostain J, Wu FC. Testosterone deficiency syndrome (TDS) needs to be named appropriately: The importance of accurate terminology. Eur. Urol. 50: 407-409 (2006) https://doi.org/10.1016/j.eururo.2006.07.001
  26. Taylor WG, Elder JL, Chang PR, Richards KW. Microdetermination of diosgenin from fenugreek (Trigonella foenum-graecum) seeds. J. Agr. Food Chem. 48: 5206-5210 (2000) https://doi.org/10.1021/jf000467t
  27. Sato K, Fujita S, Iemitsu M. Acute administration of diosgenin or dioscorea improves hyperglycemia with increases muscular steroidogenesis in STZ-induced type 1 diabetic rats. J. Steroid Biochem. 143: 152-159 (2014) https://doi.org/10.1016/j.jsbmb.2014.02.020
  28. Murakami T, Kishi A, Matsuda H, Yoshikawa M. Medicinal foodstuffs XVII. Fenugreek seed. (3): Structures of new furostanol-type steroid saponins, trigoneosides Xa, Xb, XIb, XIIa, XIIb, and XIIIa, from the seeds of egyptian trigonella foenumgraecum L. Chem. Pharm. Bull. 48: 994-1000 (2000) https://doi.org/10.1248/cpb.48.994
  29. Shea JL, Wong PY, Chen Y. Free testosterone: Clinical utility and important analytical aspects of measurement. Adv. Clin. Chem. 63: 59-84 (2014) https://doi.org/10.1016/B978-0-12-800094-6.00002-9
  30. Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. Biol. Reprod. 85: 431-441 (2011) https://doi.org/10.1095/biolreprod.111.092593
  31. Duffy MJ. PSA in screening for prostate cancer: More good than harm or more harm than good? Adv. Clin. Chem. 66: 1-23 (2014) https://doi.org/10.1016/B978-0-12-801401-1.00001-3
  32. Rick FG, Schally AV. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol. Oncol.-Semin. O. I. 33: 270-274 (2015)
  33. Barqawi A, Crawford ED. Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int. J. Impot. Res. 18: 323-328 (2006) https://doi.org/10.1038/sj.ijir.3901418
  34. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A-Biol. 60: 1451-1457 (2005) https://doi.org/10.1093/gerona/60.11.1451
  35. Schubert M, Jockenhovel F. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. J. Endocrinol. Invest. 28: 23-27 (2005) https://doi.org/10.1007/BF03345525
  36. Seo SM, Jeong YS, Hari DK, Shin DH, Lee IJ, Park ES, Lee JD, Hwang YH. Variation of pinitol content for domestic legume species in korea. Korean J. Crop. Sci. 56: 50-56 (2011) https://doi.org/10.7740/kjcs.2011.56.1.050
  37. Kerksick CM, Wilborn CD, Campbell WI, Harvey TM, Marcello BM, Roberts MD, Parker AG, Byars AG, Greenwood LD, Almada AL, Kreider RB, Greenwood M. The effects of creatine monohydrate supplementation with and without D-pinitol on resistance training adaptations. J. Strength Cond. Res. 23: 2673-2682 (2009) https://doi.org/10.1519/JSC.0b013e3181b3e0de
  38. Schroeder, ET, Terk M, Sattler FR. Androgen therapy improves muscle mass and strength but not muscle quality: Results from two studies. Am. J. Physiol.-Endoc. M. 285: E16-E24 (2003)
  39. Schroeder ET, Vallejo AF, Zheng L, Stewart Y, Flores C, Nakao S, Martinez C, Sattler FR. Six-week improvements in muscle mass and strength during androgen therapy in older men. J. Gerontol. A-Biol. 60: 1586-1592 (2005). https://doi.org/10.1093/gerona/60.12.1586
  40. Moss JL, Crosnoe LE, Kim ED. Effect of rejuvenation hormones on spermatogenesis. Fertil. Steril. 99: 1814-1820 (2013) https://doi.org/10.1016/j.fertnstert.2013.04.003
  41. Kovac J, Pastuszak AW, Lamb DJ, Lipshultz LI. Testosterone supplementation therapy in the treatment of patients with metabolic syndrome. Postgrad. Med. 126: 149-156 (2014) https://doi.org/10.3810/pgm.2014.11.2843
  42. Grober ED. Testosterone deficiency and replacement: Myths and realities. Cuaj-Can. Urol. Assoc. 8: S145-S147 (2014)
  43. Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Front. Horm. Res. 43: 1-20 (2014)
  44. Volpato S, Vigna GB, Fellin R. The benefit and risk of testosterone replacement therapy in older men: Effects on lipid metabolism. Acta Biomed. 81: 95-99 (2010)
  45. Singh AB, Tamarkar AK, Narender T, Srivastava AK. Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice. Nat. Prod. Res. 24: 258-265 (2010) https://doi.org/10.1080/14786410902836693
  46. Haeri MR, Limaki HK, Branford White CJ, White KN. Noninsulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats. Phytomedicine 19: 571-574 (2012) https://doi.org/10.1016/j.phymed.2012.01.004
  47. Vinken M. The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology 4: 158-165 (2013)

Cited by

  1. Effects of the mixture of fenugreek seeds and Lespedeza cuneata extracts on testosterone synthesis in TM3 cells oxidative stressed with H2O2 vol.59, pp.4, 2016, https://doi.org/10.3839/jabc.2016.052
  2. in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial vol.36, pp.3, 2018, https://doi.org/10.5534/wjmh.170004